Journal of Clinical Oncology
Articles in this Issue
Prospective, non-interventional, multisite evaluations of TRAQinform Immuno algorithmic quantitative treatment response analysis on treatment intent decisions in metastatic melanoma.
9529 Background: Molecular imaging plays a critical role in assessing immunotherapy response in metastatic melanoma, but c...
Molecular residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: The VICTORI study.
3629 Background: Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) is prognostic in colorectal c...
Knowledge, attitude, and practice of cardio-oncology amongst oncologists and cardiologists of south-east Asia: An Asian Cardio-Oncology Society (ACOS) survey.
e24019 Background: Asian Cardio Oncology Society (ACOS) was started in 2020 to promote awareness regarding cardio-oncology...
Patterns and incidence of brain metastases in high-grade neuroendocrine carcinomas.
e14025 Background: High-grade neuroendocrine carcinomas (HGNEC) are aggressive malignancies with early dissemination. Whil...
Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.
7516 Background: With the growing use of anti-CD38 therapies in early multiple myeloma (MM) management, there is a need fo...
Social determinants of health, diagnostic delay, and treatment abandonment in advanced lung cancer care.
e13521 Background: Social determinants of health (SDOH) significantly influence cancer outcomes, particularly in low- and...
A review of representation in clinical trials for metastatic prostate carcinoma.
e23329 Background: Metastatic prostate carcinoma is a leading cause of cancer related deaths among men in the United State...
Targeting cfDNA and NETs with DNAse I to augment CAR T-cell function and antitumor efficacy.
7531 Background: Chimeric antigen receptor (CAR) T-cell therapy induces high initial response rates in B-cell malignancies...
Signatures of biological heterogeneity associated with treatment outcome in diffuse large B-cell lymphoma.
7063 Background: Genetic subtypes of diffuse large B-cell lymphoma (DLBCL) capture biological differences between tumors t...
Subtype-specific representation of thyroid cancers in contemporary basket clinical trials (2018–2024): A pooled analysis.
e18021 Background: Basket clinical trials (BCTs) are designed to overcome histology-based drug development by enrolling pa...
Mortality trends and persistent disparities among U.S. adults with lung cancer and hypertensive diseases (1999–2023): A nationwide retrospective analysis.
e20668 Background: Hypertension is a prevalent comorbidity in patients with lung cancer and may exacerbate cardiovascular...
A phase I/IIa study to evaluate the safety and tolerability, activity, and PK of a potential novel CNTN4-targeted checkpoint inhibitor, EP0089, in patients with advanced solid tumors.
TPS2688 Background: Contactin 4 (CNTN4) has recently been identified as a novel cancer target which is overexpressed acros...
Divergent age-specific trends in colorectal cancer mortality: A 22-year analysis of the emerging early-onset crisis.
e15722 Background: Despite overall improvements in colorectal cancer (CRC) outcomes, concerning trends have emerged in you...
Impact of cell-type–specific circadian disruption in pediatric B-ALL on clock-based biomarkers with implications for chronotherapy.
6541 Background: B-cell acute lymphoblastic leukaemia (B-ALL) is the most common paediatric malignancy. While cure rates e...
A small extracellular vesicle protein-based model for ovarian cancer relapse detection and monitoring.
5564 Background: Recurrence surveillance of epithelial ovarian cancer (EOC) is a major clinical challenge, given the subop...
Burden, mortality patterns, and treatment disparities of prostate cancer across G20 countries: Insights from the Global Burden of Disease 2023 study.
5032 Background: Prostate cancer is the leading male malignancy in G20 nations, yet cross-national disparities in detectio...
Breast cancer patient navigation to identify individual needs and offer medical and supportive care referrals.
1547 Background: Despite evidence that patient navigation (PN) improves access to comprehensive care for patients with bre...
Characteristics of tumor microenvironment in <i>STK11</i> <sup> <i>m</i> </sup> <i> TP53 <sup>m</sup> KRAS <sup>m</sup> </i> non-small cell lung cancers and survival outcomes.
e20559 Background: KRAS mutations define a molecular subgr...
The psychosocial status of children who have a parent with cancer.
12083 Background: While numerous studies have investigated the psychosocial status of children affected by childhood cance...
Antibody-drug conjugate (ADC) after ADC: Predicting survival in patients with HER2-low metastatic breast cancer with lung metastasis using artificial intelligence (AI) and radiomics.
1027 Background: With the approval of multiple antibody drug conjugates (ADCs) for HER2-low metastatic breast cancer (MBC)...
Combination of tulmimetostat and PD-1 blockade for patients with advanced non–small cell lung cancer who progressed from first or second line of treatments.
TPS8664 Background: Immune checkpoint inhibitors (ICIs) have transformed advanced non–small cell lung cancer (NSCLC) treat...
Inpatient outcomes among early-onset breast cancer hospitalizations with metabolic dysfunction–associated liver disease: A national estimate.
e12729 Background: The incidence of early-onset breast cancer(EOBC) continues to rise globally. Metabolic dysfunction-asso...
Building a real-time cancer data mart (CDM) for an integrated health system, leveraging traditional natural language processing (NLP) methods, curated data sources, and large language models (LLMs).
e13654 Background: Timely cancer case ascertainment is critical for supporting clinical trials, research, and operational...
Central nervous system metastases in gynecologic cancers: Real-world outcomes and prognostic factors.
e14012 Background: CNS metastases from gynaecologic cancer (GC) are uncommon and evidence guiding management is limited. W...
Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
7510 Background: Tec, a B-cell maturation antigen x CD3 bispecific antibody (bsAb), and Tal, a G protein-coupled receptor...